Clinical Observation Of Gelanxinning Soft Capsule In The Treatment Of Unstable Angina Pectoris And Its Effect On Serum AngⅡ And ICAM-1

Purpose:To observe the clinical efficacy of Gelanxinning Soft Capsule in the treatment of unstable angina pectoris(UAP),phlegm and stasis mutual obstruction syndrome and its influence on serum Angiotensin Ⅱ(Ang Ⅱ)and Intercellular adhesion molecules-1(ICAM-1).Explore its mechanism of action.Material and method:The subjects in this study were selected from 160 patients with unstable angina pectoris of phlegm and stasis mutual obstruction syndrome who met the inclusion criteria and volunteered to participate in the study.According to the principle of random control,subjects were divided into the treatment group and the control group,with 80 cases each.The control group were treated with the modern western medicine standardization,the treatment group were treated with Gelanxinning soft capsule on the base of rmodern western medicine standardization.Observe the angina symptom scores and TCM syndrome scores before and after treatment in the two groups,and evaluate the clinical efficacy.Determination of Ang II and ICAM-1 before and after treatment by enzyme-linked immunosorbent assay,andcomparative analysis.Results:1.Efficacy of the angina symptoms:after the end of treatment,the total effective rate of treatment group was 97.47% and the control group was 93.59%.The treatment group was significantly better than the control group,and the efficacy of angina symptoms was statistically significant difference(P < 0.01).2.Efficacy of the TCM symptoms:after the end of treatment,the total effective rate of treatment group was 96.20% and the control group was 89.74%.The treatment group was significantly better than the control group,and the efficacy of angina symptoms was statistically significant difference(P < 0.01).3.AngⅡlevel:after the end of treatment,the level of AngⅡ in the two groups were decreased,and the decrease degree in the treatment group was more significant than that in the control group,with significant differences(P < 0.01).4.ICAM-1 level:after the end of treatment,the level of ICAM-1 in the two groups were decreased,and the decrease degree in the treatment group was more significant than that in the control group,with significant differences(P < 0.01).5.Safety comparison:no No significant adverse reactions occurred in the two groups of patients during the treatment.Conclusion:1.Gelanxinning Soft Capsule can significantly improve the clinical symptoms of patients and TCM sydnromes in patients with unstable angina pectoris,phlegm and stasis mutual obstruction syndrome.2.The mechanism of action of Gelanxinning Soft Capsule in patients with unstable angina pectoris,phlegm and stasis mutual obstruction syndrome by decreased the expression levels of angiotensin II and intercellular adhesion molecule-1 in serum.3.Gelanxinning Soft Capsule has significant curative effect on the treatment of unstable angina pectoris,phlegm and stasis mutual obstruction syndrome and safety.